

A global pharmaceutical company that promotes health and welfare for all



www.celltrion.com/en-us

# Celltrion, Inc.

CEO Kee Woo Sung

Location 23 Academy-ro, Yeonsu-gu, Incheon Metropolitan City

Specialty Biosimilars, New Drugs, Small Molcules

Tel / Fax / E-mail T. 82-32-850-5000 E. Contact@celltrion.com Celltrion, Inc. is a leading Korean biopharmaceutical company that launched the world's very first antibody biosimilar product, Remsima<sup>®</sup>. As one of the first companies to chart the Korean biopharmaceutical sector, Celltrion pioneered many previously unexplored areas and evolved into one of the leaders in the biosimilar development and manufacturing sector with numerous milestone achievements. The company now plans to keep the momentum and continue the legacy as it ventures into new business areas such as small molecule pharmaceuticals and Ubiquitous-healthcare system with unique Celltrion approaches.

# Main Products



## Biopharmaceutical

| Product             | Reference<br>Product | INN   | Indications   |
|---------------------|----------------------|---|---|
| Remsima SC          | -                    | Infliximab  | Rheumatoid Arthritis  |
| Remsima / Inflectra | Remicade             | Infliximab  | Rheumatoid Arthritis, Ankylsoing Spondylitis, Ulcerative Colitis,<br>Crohn's Disease, Psoriasis |
| Truxima             | Rituxan              | Non-Hodgkin's Lymphoma, Chronic Lymphocytic<br>Rituximab Rheumatoid Arthritis, Granulomatosis with Poly<br>Microscopic Polyangiitis |   |
| Herzuma             | Herceptin            | Trastuzumab   | HER2-Positive Metastatic Breast Cancer, Early Breast Cancer,<br>Metastatic Gastric Cancer       |

Herzuma

#### Small molecule

| Product   | Ingredient | Indications  |
|-----------|------------|--|
| Linezolid | Linezolid  | Pneumonia, Skin and Skin Structure Infections,<br>Vancomycin-resistant Enterococcus faecium Infections |

## **R&D** Pipeline

### **Antibody Biosimilars**

| Project | INN         | Original | Indications  | Status   |
|---------|-------------|----------|--|----------|
| CT-P39  | Omalizumab  | XOLAR®   | Asthma, Urticaria  | Research |
| CT-P17  | Adalimumab  | HUMIRA®  | Rheumatoid arthritis, Psoriatic arthritis, IBD                   | Phase3   |
| CT-P16  | Bevacizumab | AVASTIN® | Metastatic Colorectal Cancer, Metastatic<br>Breast Cancer, NSCLC | Phase3   |

#### **New Antibodies**

| Project | Indications                 | Status   |
|---------|-----------------------------|----------|
| CT-P59  | COVID-19                    | Research |
| CT-P27  | Pandemic Seasonal influenza | Phase2   |

| IMDs    |                |                |
|---------|----------------|----------------|
| Project | Indications    | Status         |
| CT-G20  | Cardiomyopathy | Clinical trial |